Age: 48.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Mobility decreased, Pneumonia legionella, Pyrexia
Clinical narrative: Legionnaire's disease; Mobility decreased; Fever; This spontaneous case was reported by a consumer and describes the occurrence of PNEUMONIA LEGIONELLA (Legionnaire's disease) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis. Concomitant products included INFLUENZA VACCINE (FLU VACCINE VII) for an unknown indication.   On 26-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PNEUMONIA LEGIONELLA (Legionnaire's disease) (seriousness criterion medically significant), MOBILITY DECREASED (Mobility decreased) and PYREXIA (Fever). At the time of the report, PNEUMONIA LEGIONELLA (Legionnaire's disease), MOBILITY DECREASED (Mobility decreased) and PYREXIA (Fever) outcome was unknown.            No concomitant medication provided. No treatment information mentioned.  Patient experienced legionnaires disease. Took COVID vaccine and flu vaccine on the same day and could not move. Got a fever as well.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company comment: This spontaneous case concerns a 48 year old female patient with concurrent condition of rheumatoid arthritis, who experienced the unexpected serious (medically significant) event of Pneumonia legionella, unknown days after receiving the second dose of mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the first dose with the same vaccine about a month ago with no reported adverse events. No information on exact date of the event, detailed clinical course, relevant investigations, treatment and outcome of the event was available in the report. Co-suspect adalimumab could be a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 48 year old female patient with concurrent condition of rheumatoid arthritis, who experienced the unexpected serious (medically significant) event of Pneumonia legionella, unknown days after receiving the second dose of mRNA-1273 vaccine in the COVID-19 vaccination series. The patient received the first dose with the same vaccine about a month ago with no reported adverse events. No information on exact date of the event, detailed clinical course, relevant investigations, treatment and outcome of the event was available in the report. Co-suspect adalimumab could be a risk factor for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.